CYP7A1 and cholestasis: Our results confirm that it is important to consider both: molecular effects and the adverse outcome at the same time, before concluding on a specific AOP: Even if some molecular changes observed in our study point to cholestasis (i.e. alterations in the expression of Cyp3a1/2 and Cyp7a1), the related adverse outcome was not observed.